Miller Aine (CIK 2012524) reported 10 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-24). Recent activity: Sell TBPH (93,108 shares), Sell TBPH (96,718 shares), Sell TBPH (6,258 shares), Buy TBPH (18,750 shares), Sell TBPH (6,827 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-24 | Theravance Biopharma, Inc. (TBPH) | SVP, DEV & HEAD OF IRE OFFICE | Sell | 93,108 | $0 |
| 2026-09-24 | Theravance Biopharma, Inc. (TBPH) | SVP, DEV & HEAD OF IRE OFFICE | Sell | 96,718 | $0 |
| 2026-08-24 | Theravance Biopharma, Inc. (TBPH) | SVP, DEV & HEAD OF IRE OFFICE | Sell | 6,258 | $106,073 |
| 2026-06-23 | Theravance Biopharma, Inc. (TBPH) | SVP, DEV & HEAD OF IRE OFFICE | Buy | 18,750 | $0 |
| 2026-05-22 | Theravance Biopharma, Inc. (TBPH) | SVP, DEV & HEAD OF IRE OFFICE | Sell | 6,827 | $112,987 |
| 2026-02-24 | Theravance Biopharma, Inc. (TBPH) | SVP, DEV & HEAD OF IRE OFFICE | Sell | 16,851 | $331,291 |
| 2025-11-24 | Theravance Biopharma, Inc. (TBPH) | SVP, DEV & HEAD OF IRE OFFICE | Sell | 6,989 | $125,103 |
| 2025-08-22 | Theravance Biopharma, Inc. (TBPH) | SVP, DEV & HEAD OF IRE OFFICE | Sell | 6,989 | $93,583 |
| 2025-05-21 | Theravance Biopharma, Inc. (TBPH) | SVP, DEV & HEAD OF IRE OFFICE | Buy | 10,430 | $0 |
| 2025-05-21 | Theravance Biopharma, Inc. (TBPH) | SVP, DEV & HEAD OF IRE OFFICE | Sell | 9,701 | $91,674 |
来源：SEC Form 4 申报文件 · 截至 2026-09-24